Bristol-Myers raises stakes in bid for ImClone
September 25th, 2008 by 
admin Bristol-Myers Squibb increased the push on ImClone by upbringing its effort for the wager in the engineering consort it does not already possess to $4.7bn and stating that it intends to verify the substance to ImClone’s shareholders
Tags: NCR
Posted in Pharmaceuticals | 